1) Background: BET bromodomain proteins regulate transcription by binding acetylated 8 histones and attracting key factors for e.g. transcriptional elongation. BET inhibitors have been 9 developed to block pathogenic processes such as cancer and inflammation. Despite having potent 10 biological activities, BET inhibitors have still not made a breakthrough in clinical use for treating 11 cancer. Multiple resistance mechanisms have been proposed but thus far no attempts to block this 12 in glioma has been made. (2) Methods: Here, we have conducted a pharmacological synergy screen 13 in glioma cells to search for possible combination treatments augmenting the apoptotic response to 14 BET inhibitors. We first used HMBA, a compound that was developed as a differentiation therapy 15 four decades ago but more recently was shown to primarily inhibit BET bromodomain proteins.
malignancies respond to BETis in vitro by cell cycle arrest, differentiation and apoptosis, whereas 48 glioma cells undergo cell cycle arrest and differentiation and to a lesser extent apoptosis (13) (14) (15) .
49
Importantly for glioma treatments, the clinical BET inhibitor OTX015 has been shown to pass the 50 blood-brain-barrier (16) .
51
If BETis are to work in the clinic against solid tumors including glioma, then the predominant effect 52 of BETis should be apoptosis. So far, BETis have not convincingly shown this effect as single agents 53 in solid tumors. Here we use the C6 rat glioma model system to study means to activate cell death in 54 BETi-treated cells. We demonstrate that the MAPK pathway is critical for maintaining viability of 
58
To study the effect of HMBA in glioma we used the rat glioma cell line C6. Treatment of these cells 59 for 72 hours blocked cell proliferation ( Figure 1A ) but did not induce apoptosis, as assessed by flow 60 cytometry of sub-G1 DNA content ( Figure 1B-C) . We therefore conclude that C6 glioma cells 61 primarily respond to HMBA by growth inhibition. Since apoptosis is the preferred mode of effect of 62 cancer treatment we hypothesized that a signaling pathway targeted by drugs could be used by the 63 cell to maintain viability upon HMBA treatment. We therefore screened a library of 226 compounds 64 ( Supplemental Table S1 ) either approved for clinical use or under various stages of clinical DNA histograms of 7-AAD-stained nuclei quantifying the sub-G1 content together indicate that the primary response to HMBA-treatment in C6 glioma cells is growth arrest. c) Quantification of cells with less than diploid DNA content in b). d) Plot summarizing the results from the pharmacological screen of HMBA in combination with 226 different compounds. The three red dots indicate the three MEK inhibitors which all fall below the line of equal measured and expected. Funck-Brentano et l., BioRxiv 2019 3 of 10 development. Comparing the effect of monotherapy of HMBA, with monotherapy of either library 66 compound alone or with combination therapy of HMBA and library compound, we identified 67 compounds that displayed synergistic effects together with HMBA, of which three were MEK 68 inhibitors ( Figure 1D ).
70
Currently, two MEK inhibitors are FDA approved for use in melanoma but none are used for 71 treatment of glioma. We repeated the results from the library screen using the FDA-approved MEK- inhibitor trametinib (GSK1120212) in a clonogenic assay ( Figure 2A ). The lack of long-term growth 73 and induction of cell death was revealed by an ATP/luciferase-based viability assay ( Figure 2B ) and 74 flow cytometric analysis of sub-G1 DNA content ( Figure 2C ). This cell death was likely mediated by 75 caspases since the sub-G1 content of the cells could be rescued by the pan-caspase inhibitor Q-VD-
76
OPH. Furthermore, the synergistic effects of dual BET and MEK inhibition could be reproduced using 77 other MEK inhibitors (TAK-733 and AZD8330, but not binimetinib) and BETi (JQ1 or iBET-762; Figure   78 2D-E and Supplemental Figure S1A drug resistance pump such as p-glycoprotein (ABCB1 or MDR1) but such a link could not be 83 established. On the other hand, trametinib had previously been shown to be a substrate of p-84 glycoprotein (p-gp) (18) so we reasoned that p-gp could be involved in the synergy in C6 glioma cells.
85
Indeed, as previously shown (19), C6 cells were highly effective in pumping out the substrate 86 rhodamine 123, and this activity was blocked by the ABCB1/ABCG2 inhibitor elacridar ( Figure 3A ).
87
Interestingly, also trametinib -but not the other MEK inhibitors tested -could inhibit pumping of 88 rhodamine 123 but only occasionally at 1 µM and more prominently at > 1µM (Supplemental Figure   89 3A-B). Blocking of pumps with elacridar reduced the concentration needed to inhibit ERK 90 phosphorylation in C6 cells ( Figure 3B ). However, the fact that elacridar neither synergized with 
96
Next, we investigated if HMBA and trametinib could block tumor growth in vivo. Immuno-97 compromised NOG mice were transplanted with C6 cells subcutaneously, and when tumors were 98 palpable they were randomized to treatment either with normal food or food containing trametinib 99 and/or normal drinking water or drinking water supplemented with HMBA. Tumors in mice treated 100 with HMBA in drinking water or trametinib in the food grew significantly slower than tumors 101 growing in control mice and in HMBA/trametinib-treated mice tumor growth was robustly 102 suppressed resulting in four-fold longer survival ( Figure 4A-B ).
104
To gain insight into whether or not the described synergy effect of BET and MEK inhibition would 105 also impact on human glioma we treated four patient-derived glioma sphere cultures with HMBA 106 and trametinib. Three out of the four cell lines had some response to trametinib in short-term sphere 107 culture but only one out of the four cell lines, NCH421K, was sensitive to the combination, suggesting 108 that multiple pathways maintain viability of human glioma cells treated with HMBA ( Figure 5A ).
109
However, long-term adherent culture of NCH644 and NCH690 revealed sensitivity to the 110 combination ( Figure 5B ). Nevertheless, treatment of mice bearing NCH421K tumors with HMBA 111 water and trametinib food suppressed growth ( Figure 5C ). Trametinib has been associated with 112 induction of kinase activities in triple-negative breast cancer cells through enhancer remodeling (20).
113
Presumably, this could help the cells survive MEK inhibition, which would be perturbed by BETi 114 treatment if these kinases rely on BET protein-regulated processes for expression. In order to Figure 5B) . The NCH644 line, on the other hand, was 123 less affected by monotherapy with trametinib ( Figure 5B ) and phosphorylation of for example c-Jun,
124
FYN and PRAS40 was induced by trametinib ( Figure S4 ). Collectively, our data does not provide a 
Discussion

129
In the present study we have identified means to enhance efficacy of BETis in models of glioma.
130
Several BETis have already entered clinical trials, e.g. HMBA, OTX015 and ABBV-075 (21-23), but 131 thus far the therapeutic effect of these inhibitors as monotherapies have been sparse. Our findings 132 that MEK inhibitors, which are already available in clinical use, could synergize with BETis is 133 therefore of clinical interest. Notably though, the synergistic effect of simultaneous targeting with 134 BET and MEK inhibitors has also been observed in a broad set of tumor types (20, (24) (25) (26) (27) (28) . The 135 sensitivity has been correlated to certain mutational states, like Suz12 loss in malignant peripheral 136 nerve sheath tumors (24) which leads to an epigenetic switch from histone methylation to histone 137 acetylation, rendering the tumors sensitive to BET inhibitor JQ1. Another study demonstrated that 138 resistance to MEK inhibitors associated with BRD4-induced enhancer formation, which could be 139 inhibited by JQ1 (20) . Although the combination therapy can show effects in many tumor types it is 140 not certain that the mechanism will be identical in all affected tumor types since the transcriptional 141 effects of BET inhibition is very pronounced. 
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(mm3)=(length(mm)) × (width(mm))2/2. Treatments were started when the tumors were actively 176 growing, judged by increasing volumes on repeated caliper measurements. Trametinib was mixed in 177 the chow at 2.5 mg/kg giving an approximate dose of 0.5mg/kg mouse per day. HMBA was given in 178 drinking water as 2.5% HMBA, 0.33g/L bicarbonate, 2% sucrose. Vehicle was given as 0.33 g/L 179 bicarbonate, 2% sucrose. Mice were sacrificed and tumors were harvested before or when tumors 
198
Lysates were prepared the same way as described above and 200 µg total protein was incubated with 199 each membrane set. The signals were quantified using densitometry. 
